학술논문
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation
Document Type
Article
Author
Source
In Multiple Sclerosis and Related Disorders September 2021
Subject
Language
ISSN
2211-0348